AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Archer Materials fast-tracks Biochip development with Paragraf
- Focus on at-home potassium testing for kidney health
- Collaboration expands momentum from recent healthcare partnerships
Archer Materials (ASX:AXE) has taken a significant step forward in the development of its innovative Biochip device by partnering with UK-based electronics company Paragraf. The $450,000 agreement is designed to speed up the creation of a prototype potassium-sensing chip that could transform how chronic kidney disease is monitored, particularly in home settings.
The collaboration brings together Archer's semiconductor and diagnostic capabilities with Paragraf's expertise in graphene-based electronics. At the heart of the project is the use of graphene field-effect transistors (gFETs), which promise a new level of accuracy in measuring potassium levels in blood samples.
The six-month project will be executed in two key stages. Stage 1 focuses on refining the technology by optimizing measurement protocols, boosting quality control in gFET production, and enhancing the sensor’s ability to detect potassium. These efforts are also expected to generate valuable intellectual property that will support the eventual integration of the sensor into a cartridge-based system for broader use.
In Stage 2, attention will shift to transforming lab-tested devices into more product-ready prototypes. This phase will prioritize improving the durability and reliability of the sensors to make them suitable for real-world usage in home diagnostics.
This partnership follows Archer’s recent agreement with Hylid Diagnostics to develop a complementary potassium measurement product. Hylid, which is focused on bringing lab-quality blood testing to homes, is particularly active in addressing chronic kidney disease in the North American and European markets.
Archer’s CEO Simon Ruffell emphasized the strategic value of the Paragraf partnership, noting its importance in creating a viable prototype and establishing future pathways for regulatory trials and commercial deployment.
Paragraf is a leader in the mass production of graphene-based devices using standard semiconductor processes. Its proprietary methods enhance the unique properties of graphene, making it a strong ally for Archer in creating next-generation biosensing technologies.
This development adds to Archer's growing presence in the health-tech sector and aligns with investor interest in innovative companies listed on the S&P200. Moreover, for those exploring stable income-generating opportunities in the Australian market, healthcare innovation often complements interest in ASX dividend stocks through long-term industry growth trends.
As the global demand for decentralized, real-time health monitoring rises, Archer’s forward-looking efforts may represent a notable evolution in how chronic illnesses are tracked and managed across the healthcare landscape.
